Prospera Financial Services Inc Has $5.10 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Prospera Financial Services Inc boosted its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 145.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 163,246 shares of the company’s stock after buying an additional 96,845 shares during the quarter. Prospera Financial Services Inc’s holdings in Teva Pharmaceutical Industries were worth $5,095,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP increased its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust increased its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares during the last quarter. Global Retirement Partners LLC increased its position in Teva Pharmaceutical Industries by 27.3% during the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares during the last quarter. Finally, 1620 Investment Advisors Inc. increased its position in Teva Pharmaceutical Industries by 1,823.2% during the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock worth $49,000 after buying an additional 1,495 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TEVA. Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Truist Financial boosted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, Scotiabank increased their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 1,280,269 shares of company stock worth $42,755,980. 0.54% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $34.04 on Tuesday. The firm has a market cap of $39.13 billion, a P/E ratio of 25.59, a price-to-earnings-growth ratio of 3.29 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The business’s 50 day moving average is $31.92 and its 200-day moving average is $31.09.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.